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Developments in NEW triad research
Shawn N. Whitehead, Vladimir Hachinski, Alexander Levit

In 2020, we offered Neurovascular unit (NVU)
dysregulation, Executive dysfunction, and White matter
disease as a triad of understudied pathologies that are
central to the most common and often comorbid
neurodegenerative
diseases,
vascular
cognitive
impairment (VCI) and Alzheimer disease (AD) [1]. We
considered it a helpful construct as it cuts across the
cellular, neuropsychiatric, and histological/radiological
domains of study. Since then, we have been calling it
the NEW Triad. Several key studies have advanced this
theoretical construct further.
In a study of healthy aging by Verheggen et al.,
dynamic contrast-enhanced (DCE) MRI captured a
greater propensity for blood-brain barrier (BBB)
leakage in regions of higher-order function (bilateral
orbitofrontal and cingulate cortices), that is executive
function. A greater leakage rate was seen in white
matter than in gray matter, though not statistically
significant [2]. Kerkholfs et al., demonstrated that in
patients with cerebral small vessel disease, leakage
volume in both radiologically normal appearing white
matter and white matter hyperintensities correlated with
cognitive decline over 2 years of follow-up, particularly
in the domain of executive function [3]. These studies
support prior findings that these brain regions are
inherently more vulnerable to vascular injury but
moreover, identify DCE-MRI as a potentially important
tool in both research and clinical settings. Future studies
can utilize DCE-MRI to evaluate mechanisms of
cognitive protection in interventions that target either
the NVU or systemic vascular risk factors.
Complementing these imaging tools, Hussain et al.,
summarize the many potential serum biomarkers that
could be used to detect BBB leakage [4]. Several of
these biomarkers are proteins released from cells of the
NVU. Serum biomarkers will be important in the
research and development setting as they allow for in
vivo corroboration of neuroimaging, such as DCE-MRI
studies. More importantly, in the clinical setting, serum
biomarkers of neurodegenerative processes would offer
much needed correlates for diagnosis and monitoring of
treatment response. In many settings, serum biomarkers
will continue to be far more accessible to researchers
and patients than MRI (and certainly more accessible
than specialized MRI protocols such as DCE-MRI).
A question that largely remains outstanding is the causal
relationship between the NEW triad and the various
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brain parenchymal proteinopathies, namely of amyloid
and tau, that are associated with neurodegenerative
syndromes such as AD. Given that the NEW triad has
been captured even in clinically healthy aging, that is, it
precedes clinical manifestations, it is tempting to pursue
the hypothesis that NEW triad pathology is causal.
Variations in NEW triad severity may ultimately lead to
the difference between healthy neurological aging and
decompensation of CNS homeostasis with subsequent
neurodegenerative disease. However, an important
alternative hypothesis is that toxic protein accumulation
in AD is instead the ‘upstream’ process that leads to
abluminal injury of the NVU, which then develops the
NEW triad [1]. Lastly, a hypothesis of confounding
should be considered, in which the NEW triad and
neurodegenerative proteinopathies are both independently caused by a confounding factor, such as microglial
[1] or glymphatic pathology [5].
While it would be prudent to delineate causality, the
NEW triad as a theoretical construct is hoped not to
complicate a field that is already fraught with many
unresolved hypotheses. Rather, as vascular risk factors
and glial cells are likely more accessible to therapeutic
intervention, we hope that a focus on the NEW triad
would expand the research of treatment options,
including novel therapeutic targets. Firstly, the
repurposing and optimization of well-established
treatments for hypertension, diabetes, and dyslipidemia offer many opportunities for protection of
the NVU from a luminal angle [6]. Soto-Rojas et al.,
have also outlined novel treatments including new
drug delivery systems that could protect the NVU from
the abluminal angle, such as nanoparticles, liposomes,
and so-called molecular trojan horses that rely on
receptor-mediated transcytosis [6]. Empiric therapeutic
studies in AD (or any neurodegenerative conditions
associated with the NEW triad) could be criticized as
putting the cart before the horse, as the pathophysiology of these conditions is not yet well
understood. However, in the face of a potential public
health crisis perpetuated by an overburdened long-term
care system, jumping to studies of intervention is
warranted. It is important to recall that executive
dysfunction is the largest predictor for loss of
functional independence in the context of dementia,
and thus a priority for preserving patient quality of life
and investment of healthcare resources [1].
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